Core Viewpoint - Shenzhen Huada Zhi Zao Technology Co., Ltd. is revising its 2024 employee stock ownership plan to enhance employee motivation and align with the company's strategic direction [5][11]. Group 1: Approval and Authorization - The company has obtained necessary approvals and authorizations for the revision of the employee stock ownership plan, complying with relevant regulations [5][11]. - The plan's related proposals have been submitted for review at the company's shareholders' meeting [11]. Group 2: Reasons and Main Content of the Revision - The revision aims to adjust the company's performance assessment targets to stimulate employee engagement and support sustainable business development [8][11]. - The main content of the revision includes changes to the performance assessment requirements, with specific targets set for the years 2024 and 2025 based on the company's revenue from 2023, which was 2.709 billion [8][9]. Group 3: Performance Assessment Targets - The performance assessment for the employee stock ownership plan will be based on revenue growth rates, with specific targets set for each assessment period [9][10]. - The first unlock period for 2024 has a trigger value of 15% and a target value of 20%, while the second unlock period for 2025 has a trigger value of 32% and a target value of 44% [8][9].

Core Viewpoint - The company has implemented a "Quality Improvement and Efficiency Enhancement Return Action Plan" for 2025, focusing on optimizing operations and enhancing returns to investors while navigating market challenges and opportunities [1]. Group 1: Business Performance and Strategy - The company has centered its operations around gene sequencing, leading to sustained growth across three major business lines despite competitive pressures and price declines in the industry [2][3]. - The company achieved a historical high in sales of its all-read long sequencing business (SEQ ALL), with over 700 units sold, marking a year-on-year growth of 60.35% [2]. - The company has expanded its global footprint, with cumulative sales of gene sequencing instruments exceeding 5,300 units, indicating a significant milestone [2]. Group 2: Market Expansion and Development - The company is actively pursuing a global strategy, focusing on diversifying its market presence in regions like Europe, Africa, and the Middle East to mitigate risks associated with single-market dependency [1][3]. - In the Asia-Pacific region, the company has successfully delivered 50,000 samples for the Thailand Genome Project and is advancing projects in Indonesia and South Australia [4]. - The company has established new customer relationships in various regions, including 22 new clients in the Asia-Pacific and 28 in the Americas, enhancing its market penetration [5][6]. Group 3: Product Development and Innovation - The company is advancing its product lines by integrating short-read and long-read sequencing technologies, aiming for automation and intelligent solutions in laboratory processes [9][10]. - The company has achieved significant growth in its multi-omics business, with revenue increasing by over 40% year-on-year, driven by product upgrades and market expansion [3][10]. - The company has obtained numerous certifications for its high-throughput sequencing products, enhancing its competitive edge in global markets [10]. Group 4: Financial Management and Efficiency - The company has invested approximately 1.574 billion RMB in its initial public offering projects, focusing on the development of semiconductor-based sequencing instruments and marketing service centers [8]. - The company is enhancing its financial management by improving accounts receivable turnover and optimizing credit management to accelerate cash flow [8][9]. - The company is implementing budget management strategies to align expenses with revenue forecasts, thereby improving operational efficiency [9]. Group 5: Governance and Compliance - The company has established a market value management system to enhance compliance and protect the rights of investors and stakeholders [11]. - The company has improved its ESG ratings, achieving an AA rating from Wind ESG, reflecting its commitment to sustainable development and enhancing investor confidence [11]. - The company is actively engaging with investors through various communication channels, including online and offline meetings, to foster transparency and trust [12].

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. has proposed a 2024 Employee Stock Ownership Plan (ESOP) aimed at aligning the interests of employees and shareholders, enhancing corporate governance, and promoting long-term sustainable development [3][12][16]. Group 1: Plan Overview - The ESOP is designed to comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [3][12]. - The plan will be managed by a dedicated committee, which will represent the interests of the participants and ensure compliance with legal requirements [9][25]. - The total amount to be raised through the plan is capped at RMB 37.7868 million, with each unit priced at RMB 1.00 [4][14]. Group 2: Participants and Structure - The plan will involve a maximum of 35 employees, including directors (excluding independent directors), supervisors, senior management, and core business personnel [4][13]. - The stock purchase price is set at RMB 26.15 per share, which is based on a fair valuation considering the company's performance and market conditions [15][16]. - The total shares allocated under the plan will not exceed 1.445 million shares, representing approximately 0.35% of the company's total share capital [5][18]. Group 3: Lock-up and Vesting - The plan has a duration of 48 months, with shares unlocking in two phases: 50% after 12 months and the remaining 50% after 24 months [6][21]. - The unlocking of shares is contingent upon the company's performance meeting specific revenue growth targets, which are set against the 2023 revenue of RMB 2.709 billion [22][23]. Group 4: Financial Management and Compliance - The company will not provide any financial assistance to participants, ensuring that all funding comes from employees' legal salaries and self-raised funds [4][14]. - The management committee will oversee the daily operations of the ESOP, ensuring that all actions comply with the established guidelines and protect the rights of the participants [25][30]. - The plan includes provisions for adjusting the stock purchase price in the event of corporate actions such as stock splits or dividends [16][17].

证券简称：华大智造 证券代码：688114 （二）本持股计划设立后将由公司自行管理，但能否达到计划规模、目标存 在不确定性。 深圳华大智造科技股份有限公司 （草案修订稿）摘要 深圳华大智造科技股份有限公司 二零二五年八月 深圳华大智造科技股份有限公司 2024 年员工持股计划（草案修订稿）摘要 声 明 本公司及公司全体董事、监事保证本持股计划及其摘要内容的真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 -1- 深圳华大智造科技股份有限公司 2024 年员工持股计划（草案修订稿）摘要 风险提示 （一）本持股计划需公司股东大会审议通过后方可实施，本持股计划能否获 得公司股东大会批准，存在不确定性。 （一）《深圳华大智造科技股份有限公司 2024 年员工持股计划（草案修订 稿）》（以下简称"持股计划""本计划""本持股计划"）系深圳华大智造科 技股份有限公司（以下简称"本公司""公司""华大智造"）依据《中华人民 共和国公司法》《中华人民共和国证券法》《关于上市公司实施员工持股计划试 点的指导意见》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等有关法律、行政法规、规章、规范性文件和 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-055 深圳华大智造科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会(以下简称"证监会")发布的《上市公司募集资金监管 规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规定， 深圳华大智造科技股份有限公司(以下简称"公司"或"本公司")就 2025 年半年度募集 资金存放、管理与实际使用情况作如下专项报告： 一、募集资金基本情况 (一) 实际募集资金情况 公司首次公开发行股票注册的批复》(证监许可[2022]1638号)核准，公司首次公开发行每 股面值人民币1.00元的人民币普通股(A股)41,319,475股，每股发行价格人民币87.18元， 募集资金总额人民币3,602,231,830.50元，扣除与募集资金相关的发行费用总计人民币 会计师事务所(特殊普通合伙)对截至2022年9月6日公司此次公开发行股票的募集资金到账 情况进行了审验，并出具了《深圳华大智造科技股份有限公司IPO企业首次 ...

Core Points - Shenzhen BGI Tech Co., Ltd. held the first meeting of the 2024 Employee Stock Ownership Plan on August 21, 2025, with 25 attendees representing 34,797,962 shares, accounting for 94.40% of the total shares in the plan [1][2] - The meeting approved the revised draft of the 2024 Employee Stock Ownership Plan and its summary to ensure the smooth implementation of the plan and protect the rights of shareholders [1] - The meeting also approved the revised management measures for the 2024 Employee Stock Ownership Plan, aligning with relevant regulations and actual circumstances [2] Summary by Sections Employee Stock Ownership Plan - The 2024 Employee Stock Ownership Plan was discussed and approved, with a focus on performance assessment indicators at the company level to ensure its effectiveness [1] - The plan's total shares represented by attendees was 34,797,962, with unanimous approval (100%) from those present [2] Management Measures - The management measures for the 2024 Employee Stock Ownership Plan were revised to align with the updated draft and ensure smooth implementation [2] - The voting results showed full support with no opposition or abstentions [2]

Core Viewpoint - The legal opinion letter issued by Junhe Law Firm confirms that Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. has obtained the necessary approvals and authorizations for the revision of its 2024 restricted stock incentive plan, which aims to enhance the motivation of incentive targets and align with the company's strategic direction [4][12]. Group 1: Approval and Authorization - The company has completed the necessary procedures for the revision of the incentive plan, including resolutions from the board of directors and supervisory board [4][9]. - The independent directors have publicly solicited proxy voting rights from shareholders regarding the relevant proposals for the incentive plan [5][6]. - The supervisory board has verified the list of incentive targets and issued relevant opinions [6][8]. Group 2: Reasons and Main Content of the Revision - The revision aims to adjust the performance assessment targets at the company level to stimulate the enthusiasm of incentive targets and promote sustainable business development [9][12]. - The main content of the revision includes adjustments to the performance assessment requirements in the incentive plan, with the assessment period set for the 2024-2025 fiscal years [9][11]. - The performance assessment will be based on the company's 2023 revenue of 2.709 billion yuan, excluding revenue related to public health emergencies, with specific growth targets set for each assessment year [10][11]. Group 3: Performance Assessment Targets - The performance assessment targets for the first and second vesting periods are set at 20% and 44% growth, respectively, based on the 2023 revenue [9][10]. - The assessment will also consider the sales growth of gene sequencers, with specific targets established for each year [11][12]. - Adjustments to the performance targets may occur in the event of significant corporate changes affecting revenue [10][12].

Core Viewpoint - The company has announced a stock incentive plan involving the grant of 6.555 million restricted stocks, accounting for 1.58% of the total share capital, aimed at enhancing corporate governance and retaining talent [1][3][5]. Summary by Sections Stock Incentive Plan Purpose and Principles - The purpose of the incentive plan is to improve corporate governance, establish a long-term incentive mechanism, attract and retain talent, and align the interests of shareholders, the company, and employees [1][3]. Stock Incentive Method and Source - The incentive method involves the issuance of second-class restricted stocks, sourced from repurchased shares or newly issued A-shares directed to incentive recipients [3][4]. Number of Rights Granted - The plan proposes to grant a total of 6.555 million restricted stocks, representing 1.58% of the company's total share capital of 41.56376 million shares [1][5]. Determination of Incentive Recipients - Incentive recipients include directors, senior management, core technical personnel, and key business staff, excluding independent directors and supervisors [4][5]. Distribution of Restricted Stocks - The distribution of restricted stocks among recipients is detailed, with 97.25% allocated to business backbone personnel [5]. Validity Period of the Incentive Plan - The plan is valid from the date of stock grant until all granted stocks are vested or become invalid, with a maximum duration of 36 months [6]. Granting and Vesting Conditions - The grant price for the restricted stocks is set at 26.15 yuan per share, with specific conditions for granting and vesting based on performance metrics [9][10]. Performance Assessment Metrics - The performance assessment will consider revenue growth excluding impacts from public health events, with specific targets set for the years 2024 and 2025 [12][13]. Accounting Treatment and Impact on Financial Performance - The plan's implementation will affect the company's accounting costs, with estimated expenses to be amortized over the vesting period [23][24]. Rights and Obligations of the Company and Recipients - The company retains the right to cancel unvested stocks if performance conditions are not met, while recipients must fulfill tax obligations related to the granted stocks [25][26].

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. plans to revise its 2024 restricted stock incentive plan and employee stock ownership plan to enhance employee motivation and align with the company's strategic goals in the context of the evolving market environment [10][11]. Summary by Sections Incentive Plan Overview - The incentive plan involves granting restricted stocks to key personnel, including directors, senior management, and core technical staff, to align their interests with the company's long-term performance [1][4]. Necessary Procedures - The company has followed necessary procedures, including board meetings and shareholder approvals, to implement the incentive plan and employee stock ownership plan [5][6][7]. Revision Reasons - The revision is driven by the need to adapt to changes in the external environment and to focus on increasing market share in the gene sequencing equipment sector, which is critical for long-term revenue growth [10][11]. Revised Performance Metrics - The revised performance metrics will include non-related party gene sequencing instrument sales as a key performance indicator, aiming to enhance the company's competitive position and employee engagement [11][12]. Conclusion - The independent financial advisor confirms that the revisions to the incentive plan and employee stock ownership plan have met the necessary review and disclosure obligations and are pending shareholder approval for implementation [14][15].

证券代码：688114 证券简称：华大智造 公告编号：2025-051 深圳华大智造科技股份有限公司 关于修订 2024 年限制性股票激励计划及 2024 年员工持股计划 相关文件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳华大智造科技股份有限公司（以下简称"公司"或"华大智造"）于 议，审议通过《关于公司〈2024年限制性股票激励计划（草案修订稿）〉及摘要 的议案》《关于公司〈2024年限制性股票激励计划实施考核管理办法（修订稿）〉 的议案》《关于公司〈2024年员工持股计划（草案修订稿）〉及摘要的议案》《关 于公司〈2024年员工持股计划管理办法（修订稿）〉的议案》。为发挥激励作用， 达到激励目的，公司董事会认为应当新增2024年限制性股票激励计划（以下简称 "本激励计划"）、2024年员工持股计划所涉公司层面业绩考核指标，同意对《2024 年限制性股票激励计划（草案）》《2024年限制性股票激励计划（草案）摘要公 告》 《2024年限制性股票激励计划实施考核管理办法》 《2024年员工持股计划（草 司2024年限制性股票激励计划（草案）〉 ...